3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
7
Cisplatin
7
pembrolizumab
6
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Human Papillomavirus DNA Tests
4
Fulvestrant
4
Colposcopy
4
Paclitaxel
3
Carboplatin
3
Bevacizumab
3
palbociclib
2
lenvatinib
2
Surveys and Questionnaires
2
Radiotherapy, Intensity-Modulated
2
Radiation Dose Hypofractionation
2
Radiation
2
Platinum
2
Magnetic Resonance Imaging
2
Gemcitabine
2
Fluorodeoxyglucose F18
2
Drug Therapy
2
Congresses as Topic
2
Brachytherapy
2
Biopsy
2
Axitinib
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
1,2-diaminocyclohexaneplatinum II citrate
2
ulixertinib
1
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.